ライフサイエンスコーパス: double-blind trial

1 l Infections) was a prospective, randomized, double-blind trial.

2 abstinence were entered into this crossover, double-blind trial.

3 t failure and reduced ejection fraction in a double-blind trial.

4 disease in a randomized, placebo-controlled, double-blind trial.

5 = 30) or placebo (n = 31) for 7 days in this double-blind trial.

6 olitis has not been studied in a controlled, double-blind trial.

7 hritis (TEAR) study is a 2-year, randomized, double-blind trial.

8 untries in a randomized, placebo-controlled, double-blind trial.

9 multicentre, randomised, placebo-controlled, double-blind trial.

10 mized to GA or placebo (PBO) in this 3-year, double-blind trial.

11 andomized, multi-center, placebo-controlled, double-blind trial.

12 nrolled in a placebo-controlled, randomized, double-blind trial.

13 er 100 mg FeSO(4) or a placebo for 6 wk in a double-blind trial.

14 and C (1000 mg per day) or to placebos in a double-blind trial.

15 SO(4) or a placebo twice daily for 6 wk in a double-blind trial.

16 or fluoxetine were assessed after a 6-week, double-blind trial.

17 or to placebo, during the subsequent 28-week double-blind trial.

18 IGNITE4 was a prospective, randomized, double-blind trial.

19 withdrawal, multicenter, placebo-controlled, double-blind trial.

20 of findings from open-label series and small double-blind trials.

21 hey were based on the results of randomized, double-blind trials.

22 g) once daily for 6 or 9 months in 4 similar double-blind trials.

23 sk for CDI recurrence in 2 large randomized, double-blind trials.

24 am induction in a single center, randomized, double-blinded trial.

25 en using permuted-block randomisation in non-double-blinded trials.

26 In a double-blind trial, 157 inpatients with a history of sub

27 In a three-year, double-blind trial, 160 patients with coronary disease,

28 izumab intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were ch

29 at of a control.In a randomized, controlled, double-blinded trial, 220 participants aged 18-60 y with

30 In a double-blind trial, 225 adults underwent randomization.

31 In this randomized, 2 x 2 factorial, double-blind trial, 2400 infants were randomly assigned

32 In this randomized, placebo-controlled, double-blind trial, 25 patients were treated with either

33 In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on ant

34 In this randomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of

35 In a double-blind trial, 499 patients aged 14 years or older

36 Data were pooled from 10 double-blind trials (6699 patient-years of follow-up).

37 In a double-blind trial, 73 patients (median age, 63 years; 2

38 In a prospective, double-blind trial, acute liver failure patients without

39 In this multicenter, randomized, double-blind trial, adolescent and adult patients (age,

40 In a randomized, double-blind trial, adults with acute bacterial skin and

41 In a 12-week randomized, double-blind trial, ALS and MS patients with clinically

42 abatrin (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment.

43 Dar es Salaam, Tanzania, were enrolled in a double-blind trial and provided daily supplements of pre

44 Larger scale, randomized, double-blind trials are needed to validate the role of s

45 This randomized double-blind trial assessed the potential additional imp

46 is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerabi

47 We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospi

48 We performed a double-blind trial at a tertiary care hospital in India.

49 We did this multicentre, double-blind trial at four general hospitals in northern

50 sed, parallel-treatment, placebo-controlled, double-blind, trial at 81 sites in the Europe and the US

51 r-infant pairs were enrolled in a randomised double-blind trial between September, 2001, and October,

52 In this multicentre, double-blind trial, between Oct 21, 2013, and Oct 30, 20

53 oup (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postm

54 TIENTS: Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010.

55 In this parallel placebo-controlled double-blinded trial, children aged 3-12 years with >4 w

56 This randomized, double-blind trial compared a regimen of 7 to 12 days of

57 A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5

58 This multicenter, randomized, double-blind trial compared fluconazole (N = 295) versus

59 Randomized, controlled, double-blind trial compared RRR-alpha-tocopherol (1200 I

60 This randomized double-blind trial compared the impact of PCV13 versus P

61 We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent w

62 ional Review Board (IRB)-approved randomised double-blind trial comparing active to sham deep brain s

63 A 24-week randomized double-blind trial comparing ALC (3,000 mg per day) with

64 rdial Infarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in p

65 We performed a post hoc analysis of a double-blind trial comparing fondaparinux with placebo.

66 d of a prospective, randomized, multicenter, double-blind trial comparing polymer-free SES with place

67 We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50

68 ARTICIPANTS: Randomized, placebo-controlled, double-blind trial conducted at 2 US academic hospitals

69 The study was a randomized, double-blind trial conducted at 30 hemodialysis units at

70 phase 1/2, dose-finding, placebo-controlled, double-blind trial conducted at the University Hospitals

71 Randomized, double-blind trial conducted in 3 sites in the Pacific N

72 In a randomized, double-blind trial conducted in 399 adults > or = 65 yea

73 In this double-blind trial conducted on Pemba Island, Tanzania,

74 pose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safet

75 multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of t

76 enrolled in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3

77 In a multicenter, double-blind trial, eligible adults with acute pericardi

78 This randomized clinical double-blind trial enrolled participants at 2 clinical s

79 A randomized, double-blind trial evaluated citalopram at target doses

80 s phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel a

81 This randomized, double-blind trial evaluated the efficacy and safety of

82 This double-blind trial evaluated the safety and efficacy of

83 ansplantation) was a randomized, controlled, double-blind trial evaluating the effect of etanercept v

84 mpted and the first prospective, randomized, double-blind trials ever performed in transplantation.

85 DESIGN, SETTING, AND PARTICIPANTS: Double-blind trial examining changes in the neural circu

86 In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we

87 elapse was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients,

88 either IMT (n = 38) or placebo (n = 37) in a double-blind trial for six months, with continuation of

89 Few double-blind trials have compared longer-term efficacy a

90 In a multicenter double-blind trial, hospitalized severely malnourished c

91 We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care

92 1 week, in a placebo-controlled, randomized, double-blind trial in 60 patients with bipolar depressio

93 We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (>=1

94 In a double-blind trial in Dar es Salaam, Tanzania, we random

95 llel-group, multicenter, placebo-controlled, double-blind trial in Japan, 106 ASD individuals (18-48

96 This study was a randomized, double-blind trial in patients aged >18 years with ABSSS

97 We performed a 15- to 24-month, multicenter, double-blind trial in patients with advanced Parkinson d

98 This was a 39-center, double-blind trial in patients with definite MS of any c

99 r, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modifie

100 undertook a randomised, placebo-controlled, double-blind trial in three South African sites in sexua

101 postmenopausal women participated in a 6-mo double-blind trial in which 40 g protein as part of a Na

102 We conducted a randomized, double-blind trial in which adults with acute bacterial

103 ENGAGE AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrill

104 We conducted a multicenter, double-blind trial in which patients with type 2 diabete

105 We performed a multicenter, double-blind trial in which patients with type 2 diabete

106 ed phase 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurab

107 erformed a pooled analysis of data from four double-blind trials in which 1748 patients were randomly

108 d patient-level database from 4 prospective, double-blind trials in which 3445 patients were randomiz

109 eluting stents or bare-metal stents and five double-blind trials in which 3513 patients were randomly

110 studied in a randomized, placebo-controlled, double-blinded trial in 110 human immunodeficiency virus

111 asma specimens obtained during a randomized, double-blinded trial in antiretroviral therapy (ART)-nai

112 This monocentric, placebo-controlled, double-blind trial included 132 patients with grass poll

113 This randomised double-blind trial included 9270 patients with chronic k

114 In a randomized, multicenter, double-blind trial, inhaled iloprost (5 mug) or placebo

115 In a randomized, double-blind trial involving 135 patients with severe eo

116 The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ven

117 We conducted a 56-week, double-blind trial involving 3731 patients who did not h

118 We conducted a multicenter, randomized, double-blind trial involving nulliparous women who were

119 We conducted a multicenter, prospective, double-blind trial involving outpatient adults and child

120 We performed a randomized, double-blind trial involving patients recruited within 3

121 conducted a randomized, placebo-controlled, double-blind trial involving patients who had had a mild

122 In a double-blind trial involving patients with end-stage ren

123 In two multicenter, randomized, double-blind trials involving 448 patients with ARDS fro

124 For non-double-blinded trials larger than 200 participants, inve

125 Five randomized double-blind trials lasted 12-16 weeks and treated 1,293

126 domized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted be

127 We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving

128 ll patients exposed to ranolazine during the double-blind trials (n = 972) preceding the ROLE program

129 f age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous inject

130 We performed a double-blind trial of 152 adults with gastroparesis at 4

131 We performed a double-blind trial of 190 patients with IBS (according t

132 We performed a double-blind trial of 204 patients (78% Caucasian; 67% f

133 DESIGN, SETTING, AND PATIENTS: Randomized, double-blind trial of 300 women aged 18 to 55 years with

134 , we conducted a single-center, prospective, double-blind trial of 39 patients with mucinous-type pan

135 rtraline were randomly assigned to a 28-week double-blind trial of 50-200 mg/day of sertraline or pla

136 We performed a double-blind trial of 81 patients with active UC randoml

137 re, we report the results of a multi-center, double-blind trial of 816 children with acute gastroente

138 We performed a multicenter, double-blind trial of 99 adults with active EoE randomly

139 nrolled in a randomized, placebo-controlled, double-blind trial of a nonselective beta-blocker used t

140 first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for

141 We performed a prospective double-blind trial of adult patients with a recent (<8 w

142 olled in a national multicenter, randomized, double-blind trial of an acellular pertussis vaccine.

143 As part of a randomized, double-blind trial of antifungal prophylaxis in liver tr

144 A multicenter, randomized, double-blind trial of aspirin (300 mg/day) and folate su

145 We performed a randomized, double-blind trial of aspirin as a chemopreventive agent

146 Conclusion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HC

147 -year, prospective, multicenter, randomized, double-blind trial of early CCS withdrawal in 386 kidney

148 ndred forty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and val

149 In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65

150 ecified nested analysis within a randomized, double-blind trial of ezetimibe/simvastatin versus place

151 In a randomized, double-blind trial of healthy volunteers, we found oral

152 In this multicenter, randomized, double-blind trial of high-dose erythropoietin, we assig

153 Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs s

154 openia) in a randomized, placebo-controlled, double-blind trial of levofloxacin (P = .01).

155 We conducted a randomized, double-blind trial of low-dose methotrexate (at a target

156 -targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant pr

157 multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class I

158 We performed a phase 3, double-blind trial of patients who completed golimumab i

159 We then performed a double-blind trial of patients with IBS (mean age, 31 y;

160 We conducted a single-center, randomized, double-blind trial of perioperative subcutaneous pasireo

161 multicenter, randomized, placebo-controlled, double-blind trial of placebo versus nasal mometasone in

162 BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone

163 le Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patie

164 We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 9

165 We conducted a multisite, randomized, double-blind trial of risperidone as compared with place

166 We conducted a double-blind trial of SER-287 in 58 adults with active m

167 ination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia

168 d a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbind

169 se III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 0

170 We did a randomised, placebo-controlled, double-blind trial of the effect of intermittent prevent

171 We performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 80

172 hin-subjects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (als

173 We conducted a placebo-controlled, double-blind trial of the prophylactic effect of vitamin

174 ients enrolled in a prospective, randomized, double-blind trial of traumatic hypovolemic shock, HSD (

175 and August 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or

176 were recruited for a randomized, controlled, double-blind trial of vitamin D supplementation in pregn

177 wheat bran fiber (WBF) study, a randomized, double-blind trial of WBF as a means of decreasing the p

178 ysis of data from two replicate, randomised, double-blind trials of 12 months' duration (Sept 25, 200

179 Results of 2 multicenter, randomized, double-blind trials of 1510 adults with ABSSSI were pool

180 che-sponsored randomised placebo-controlled, double-blind trials of 75 mg twice a day oseltamivir in

181 ndertaking the major investment required for double-blind trials of a potential disease-modifying dru

182 We did three phase 1, placebo-controlled, double-blind trials of ZPIV with aluminium hydroxide adj

183 A randomised double-blinded trial of 3 pyrethroid LLIN products (10,5

184 conducted a placebo-controlled, randomized, double-blinded trial of alendronate (10 mg/day orally) (

185 One-year results of a randomized, double-blinded trial of Thymoglobulin versus Atgam for i

186 ned to overcome the shortcomings of previous double-blinded trials of household water treatment in lo

187 We conducted two prospective, randomized, double-blind trials: one involving children and the othe

188 In this randomized, double-blind trial, outpatients with schizophrenia (n=55

189 In this phase 3, randomised, double-blind trial, patients were enrolled across 141 si

190 In this double-blind trial, patients were randomized to receive

191 In a double-blind trial, patients were randomized to tolvapta

192 In this phase 3, double-blind trial, patients were randomly assigned (1:1

193 In this phase 3, double-blind trial, patients were randomly assigned (2:1

194 lled, four-sequence, four-period, crossover, double-blind trial, patients with multiple sclerosis who

195 In a double-blind trial, patients with peripheral artery dise

196 These three multicenter, prospective, double-blind trials performed at 55 transplant centers o

197 ek, phase 3, randomized, placebo-controlled, double-blind trials performed from July 15, 2010, to Apr

198 nalysis was conducted for 3 doravirine (DOR) double-blind trials (Phase IIb: P007 [NCT01632345]; Phas

199 ascular markers, we conducted a multicenter, double-blind trial, randomizing 278 participants with st

200 he DAPT (Dual Antiplatelet Therapy) Study, a double-blind trial, randomly assigned 11 648 patients wh

201 (There are no large, prospective, randomized double-blind trials testing the efficacy of IE prophylax

202 ial 2) was a randomized, placebo-controlled, double-blind trial that assessed the effects of fludroco

203 spirin with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspir

204 EVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patie

205 The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmeno

206 TART trial was an international, randomised, double-blind trial that recruited patients with unresect

207 posed by ARIA-GA(2) LEN, to investigate in a double-blind trial the efficacy and safety of AIT in dua

208 In this phase 3 double-blind trial, the authors evaluated the weight pro

209 In this double-blind trial, the infants were randomly assigned t

210 aucity of data from randomized, prospective, double-blind trials, the effect of n-3 fatty acids on de

211 onducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenici

212 conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selectiv

213 Subjects were randomized in this double-blind trial to atorvastatin 80 mg/d or placebo fo

214 We undertook a randomised double-blind trial to compare the effectiveness of chlor

215 We performed a double-blind trial to compare the efficacy and safety of

216 We did a phase 1 double-blind trial to compare the safety and immunogenic

217 We conducted a randomized, double-blind trial to determine the effect of aspirin on

218 conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquo

219 We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety o

220 Aspirin Recurrent Stroke Study, a randomized double-blind trial to evaluate the efficacy of warfarin

221 orvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastati

222 We conducted a double-blind trial to evaluate this therapeutic approach

223 We conducted a randomized, double-blind trial to examine the effect of celecoxib on

224 We performed a multicenter double-blind trial to investigate the efficacy of 3 aspi

225 Randomized, double-blind trial (treatment period, 18 months; median

226 This multicenter, randomized, partially double-blind trial used a factorial design to compare pa

227 A randomized, double-blind trial was conducted at ambulatory care cent

228 TICIPANTS: A randomized, placebo-controlled, double-blind trial was conducted in 14 gastroenterology

229 A randomized, double-blind trial was conducted in 189 volunteers aged

230 A randomized, double-blind trial was conducted in 4 countries (Afghani

231 itoneal dialysis, a multicenter, randomized, double-blind trial was conducted in 92 patients (control

232 his prospective, randomized, controlled, and double-blind trial was conducted to compare the safety a

233 This randomized, double-blind trial was conducted to determine the optima

234 The double-blind trial was terminated early because buprenor

235 phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safet

236 A randomised, placebo-controlled, double-blind trial was undertaken between October 2014 a

237 This double-blind trial was undertaken in 255 sites in 30 cou

238 This parallel group, semirandomized double-blinded trial was conducted in a single center in

239 A prospective, randomized (1:1), double-blinded trial was conducted with 100 subjects.

240 A randomized-order, crossover, double-blinded trial was performed in 14 healthy postmen

241 A double-blinded trial was performed involving 29 nonhypox

242 CTN) 0802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycop

243 In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentatio

244 In this randomized, double-blind trial, we assessed the efficacy and safety

245 In a randomized, double-blind trial, we assigned 11,506 patients with hyp

246 In this randomized, double-blind trial, we assigned 2278 patients with systo

247 In this randomized, double-blind trial, we assigned 3445 patients with sympt

248 n an international, multicenter, randomized, double-blind trial, we assigned critically ill adults to

249 In a randomized, controlled, double-blind trial, we assigned patients with chronic co

250 In this randomized, double-blind trial, we compared 4 years of therapy with

251 In this randomized, double-blind trial, we compared apixaban (at a dose of 5

252 In this randomised, double-blind trial, we compared degree of pain between s

253 In a randomized, double-blind trial, we compared hydroxyurea at a fixed d

254 In this randomized, double-blind trial, we compared parenteral amiodarone, l

255 In a randomized, double-blind trial, we compared tenecteplase plus hepari

256 In a randomized, double-blind trial, we compared the drug-coated stent wi

257 In a double-blind trial, we compared the effect of the angiot

258 In our prospective randomised double-blind trial, we enrolled adults (>40 years) with

259 In this multicenter, randomized, double-blind trial, we enrolled participants with defini

260 this international, multicentre, randomised, double-blind trial, we enrolled patients aged 18-65 year

261 his phase 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of

262 In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety

263 In this double-blind trial, we examined the possibility that ras

264 In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding ri

265 In a two-site, double-blind trial, we randomized 42 adult patients with

266 In a double-blind trial, we randomly assigned (in a 1:1 ratio

267 In a double-blind trial, we randomly assigned 14,264 patients

268 In a double-blind trial, we randomly assigned 15,828 patients

269 In a three-month, double-blind trial, we randomly assigned 209 patients wi

270 In this double-blind trial, we randomly assigned 2157 patients w

271 In this double-blind trial, we randomly assigned 225 men over th

272 In this multicenter, double-blind trial, we randomly assigned 3876 patients w

273 In this double-blind trial, we randomly assigned 5734 patients w

274 In this double-blind trial, we randomly assigned 8442 patients w

275 In a randomized, double-blind trial, we randomly assigned a total of 213

276 In this double-blind trial, we randomly assigned adults with acu

277 In this phase 2b, double-blind trial, we randomly assigned adults with pla

278 In a double-blind trial, we randomly assigned participants wi

279 In this phase 3 randomized, double-blind trial, we randomly assigned patients with h

280 In this double-blind trial, we randomly assigned patients with i

281 In a multicenter, double-blind trial, we randomly assigned patients with t

282 In this double-blind trial, we randomly assigned patients with t

283 In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at immine

284 In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio

285 In this phase 3, randomised, double-blind trial, we recruited eligible patients with

286 multicenter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections i

287 In two double-blind trials, we randomly assigned patients to re

288 Among women participating in a randomized, double-blinded trial, we assessed the effect of periodic

289 Primary outcomes after the double-blind trial were full relapse, dropout due to rel

290 The results from 2 parallel-design, double-blind trials were combined.

291 Two phase 3 randomized, double-blind trials were conducted at 154 sites in the U

292 Grantcharov and colleagues did a randomised double-blind trial which showed that training by virtual

293 In this randomized, double-blind trial, which consisted of a 56-week treatme

294 In this phase 3, double-blind trial, which was conducted at 133 centers w

295 performed a randomized, placebo-controlled, double-blind trial with 48 obese participants and used f

296 In this eight-center, randomized, double-blind trial with a 2-by-2 factorial design, we co

297 s and amiodarone, a multicenter, randomized, double-blind trial with cardiovascular outcomes that com

298 performed a large, multicenter, randomized, double-blind trial with crossover to study the efficacy

299 testinal bleeding in a prospective, phase 3, double-blind trial with parallel omeprazole suspension a

300 We conclude that double-blinded trials with consistent application of mea